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Background: The isolation frequency and susceptibility to antifungal agents of oral Candida isolates from patients
with oral candidiasis (OC) were compared between studies conducted in 2006–2007 and 2012–2013.
Methods: A total158 strains was isolated from 112 patients who visited Kagoshima University Hospital for the treatment
of OC during the 14-month period from February 2012 and March 2013, and evaluated on the isolation frequency of each
Candida strain and the susceptibility against antifungal drugs as compared to those evaluated in 2006–2007.
Results: There was a higher frequency of xerostomia as a chief complaint and of autoimmune disease in the
2012–2013 study than in the 2006–2007 study. More than 95% of Candida isolates were C. albicans and C. glabrata. In
addition, the proportion of the latter increased from 12.3% in the 2006–2007 study to 23.4% in the 2012–2013 study,
while the proportion of the former decreased from 86.2% to 72.8%, respectively. C. albicans was isolated in almost all
patients, while C. glabrata was only isolated concomitantly with C. albicans. Minimal inhibitory concentrations (MICs) were
not significantly different between groups with a few exceptions. Candida isolates, of which MICs surpassed break points,
apparently increased for miconazole and itraconazole against C. glabrata in the 2012–2013 study, but this was not
statistically significant. As a result, more cases of autoimmune disease, a greater number of C. glabrata isolates, and higher
resistance to azoles were seen in the 2012–2013 study than in the
2006–2007 study.
Conclusion: These data indicate that with recent increases in C. glabrata infection, a causative fungus of OC, and in C.
glabrata resistance to azoles, caution is needed in the selection of antifungal drugs for the treatment of OC.
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In the early 1990s, Candida albicans resistant to flucon-
azole was reported to be frequently isolated from the
oral cavity of acquired immunodeficiency syndrome pa-
tients. An epidemiological study was conducted on the
susceptibility to antifungal drugs of Candida strains iso-
lated from patients with invasive candidiasis [1]. Global* Correspondence: Kamikawa@dent.kagoshima-u.ac.jp
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unless otherwise stated.surveillance programs have been implemented for dea-
ling with candidal resistance to antifungal drugs, such as
the SENTRY program on fungi resistant to amphotericin
B in 2006–2007 [2] and reports on candidal susceptibi-
lity to candin-type antifungals [3-6]. There are 2 reports
on domestic surveillance in Japan: Surveillance 99 by the
Japan Invasive Mycosis Surveillance Study Group (JMS)
[7] and Report by Japan Antifungal Surveillance Program
(JASP) [8-10]. However, these surveillance programs fo-
cused on strains isolated from clinical cases of deep-
seated mycosis, and only 1 report, our previous studyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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iasis [11].
The isolation frequency of Candida strains is likely to
change over time, as shown by the comparisons of previ-
ous studies conducted in different time periods. For ex-
ample, C. glabrata was rarely isolated from AIDS patients
with oral candidiasis (OC) or esophageal candidiasis in
Sudo’s study published in 1997 [12]; in contrast, C. glab-
rata was detected in 12.3% of patients with OC in our
study, in which itraconazole (ITCZ) was effective despite
the existence of resistant C. glabrata against ITCZ [11]. In
addition, while resistant C. glabrata against ITCZ oc-
curred with high frequencies of 50% and 72.7% in OC and
non-OC patients of this study, respectively, [11], a previ-
ous Japanese surveillance study demonstrated resistant C.
glabrata in only 1.0–9.3% of patients with mycosis, mainly
deep-seated mycosis [7-10]. Thus, the isolation frequency
of Candida species and their resistant strains varies over
time, but no study has reported variations in frequency of
OC over time in the same health facility.
The present study was undertaken to evaluate antifun-
gal drugs against Candida strains isolated form the oral
cavity of OC patients who visited Kagoshima University
Hospital in 2012–2013 (14 months) and to assess the
isolation frequency of Candida species and their resist-
ant strains in comparison with our previous study con-
ducted in 2006–2007 (24 months) in order investigate
the use antifungal drugs in the treatment of OC.
Methods
Subjects
This study analyzed 158 strains isolated from 112 pa-
tients who visited the Department of Oral Surgery,
Kagoshima University Hospital, for the treatment of OC
during the 14-month period from February 2012 and
March 2013. Strains collected from patients having re-
ceived antifungal drug therapy within 3 months from
collection were excluded from this study.
Analysis of background variables of Candida-isolated
patients
An analysis was conducted for age, gender, underlying
systemic disease, steroid hormone use, denture use, chief
complaints, and oral disease in the 112 patients from
whom Candida was isolated.
Collection of Candida from the oral cavity and bacterial
culture
Prior to the diagnosis of OC, the affected area of the oral
cavity was wiped with a sterile cotton swab pre-immersed
in sterile physiological saline. Fluid sample collected on
the swab was smeared onto a CHROMagar Candida Cul-
ture Medium (Nippon Becton and Dickinson Company,
Ltd.) and incubated for 48 hours at 36°C.Identification of Candida species
Positive culture of Candida species was determined by
colorimetric observation of colonies in the CHROMagar
Candida culture medium containing synthetic colorimet-
ric substrates which are changed to be chromogenic by
enzymes contained in Candida species. Confirmation of
the determination of Candida species was then done by
PCR based on the method reported from Kanbe et al.,
briefly fungal cells grown in the CHROMagar Candida
culture medium were harvested by centrifugation, washed
three times with distilled water, and the DNAs were ex-
tracted and purified according to the protocol of a DNA
purification kit, Fast DNA Kit (BP Biomedical, U.S.). Then,
the DNA samples were amplified by PCR and the PCR
products were analyzed by agarose gel electrophoresis to
determine the kind of Candida species [13].Diagnosis of OC
Fluid collected on the swab from the affected area was
transferred onto a glass slide for Gram staining by a rou-
tine method. A diagnosis of OC was made when colony
formation was noted during incubation and the presence
of pseudo mycelium was shown by Gram staining [14].Evaluation of susceptibility to antifungal drugs
Candida strains detected by the above-mentioned methods
were re-seeded onto Sabouraud agar medium (Nippon
Becton and Dickinson Company, Ltd.), followed by 48-
hour incubation at 36°C. Then the culture was diluted and
adjusted to a McFarland factor of 0.5 by measuring the op-
tical density at 530 nm using a spectrophotometer ViSpec
II (Kyokuto, Japan), and applied for the assay to determine
the susceptibility. A minimum inhibitory concentration
(MIC)of each of AMPH-B, 5-FC, FLCZ, MCZ, ITCZ, and
MCFG against these Candida strains were determined
with a Yeast-like Fungal Sensitivity Kit ASTY (Kyokuto
Pharmaceutical) compatible with the National Committee
for Clinical Laboratory Standards (NCCLS) M-27A
method [15]. The kit includes 11 concentrations of each
antifungal drug in a 96-well microplate, i.e. final concentra-
tions 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8, and 16 μg/mL
for amphotericin B, miconazole, and micafungin, 0, 0.125,
0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 μg/mL for fluconazole and 5-
FC, and 0, 0.015, 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4, and
8 μg/mL for itraconazole and micafungin. The concentra-
tion “0 μg/mL” is regarded as a control. Strains with high
MIC were subjected to re-measurement of MIC with a
Yeast-like Fungal DP Eiken (Eiken Chemical) compatible
with the Clinical and Laboratory Standards Institute (CLSI)
M27-A3 method [10,16]. MIC50 and MIC90, MICs re-
quired to inhibit the growth of respective 50% and 90% of
Candida species, were calculated. Resistant strains were
determined by the following MIC criteria: AMPH-B,
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MCFG, >2 μg/mL; and ITCZ, ≥1 μg/mL.Informed consent and ethical guideline
All enrolled patients provided written informed consent
upon directly providing verbal and written detailed ex-
planation of this investigation. This study was approved by
the Human Ethics Committee of the Kagoshima Univer-
sity Medical and Dental Hospital (No.23-18 and 23–27).Statistical analysis
Fisher’s exact probability test was employed to deter-
mine differences in gender (2 × 2), chief complaints (2 ×
8), systemic disease (yes or no; 2 × 2), steroid use (2 × 2),
presence of dentures (2 × 2), oral candidiasis (2 × 4),
composition of isolated Candida species (2 × 7), and the
incidence of resistant strains between the 2006–2007
study and the 2012–2013 study. The difference in age
between the 2 studies was examined by Student’s t-test.
P value less than 0.05 was regarded as statistically
significant.Results
Background variables
As shown in Table 1, there were no statistical differences
in background variables in terms of gender, age, use of
steroid hormone treatment, presence and the kind of
systemic diseases and presence of dentures between pa-
tients in the 2006–2007 study and those of the 2012–
2013 study. Among patients with 1 chief complaint, xer-
ostomia was higher in the 2012–2013 study (23.2%) than
in the 2006–2007 study (8.8%), while tylosis linguae was
lower at 7.0% and 0%, respectively. Collectively, the
composition of chief complaints was significantly differ-
ent between the 2006–2007 patients and 2012–2013 pa-
tients as analyzed by Fisher’s exact probability test (p <
0.05). Despite no significant difference in the occurrence
of systemic disease between the 2 studies (77.2% vs.
86.6%), the presence of autoimmune diseases was higher
in the 2012–2013 study than in the 2006–2007 study
(27.6% vs. 6.7%, respectively).Classification of oral candidiasis (OC)
Classification of diagnosed OC cases is also shown in
Table 1. Among the 57 patients in the 2006–2007 study,
OC was most frequently classified as pseudomem-
braneous OC (73.7%), followed by erythematous OC
(19.3%). In the 2012–2013 study, however, erythematous
OC accounted for half (46.4%) of OC cases, followed by
pseudomembranous OC (37.5%) and mixed OC (ery-
thematous and pseudomembranous, 12.5%), but no stat-
istical difference was noted.Isolated Candida species
In total, 158 strains of Candida were isolated in patients
in the 2012–2013 study. The most frequently isolated
Candida species were Candida albicans (C. albicans, 116
strains, 73.4%), followed by C. glabrata (36 strains, 22.8%),
C. tropicalis (3 strains, 1.9%), C. parapsilosis (2 strains,
1.3%), and C. krusei (1 strain, 0.6%) (Table 2). When ana-
lyzed on a patient basis, C. albicans was isolated in all pa-
tients (n = 112), while C. glabrata was never found on its
own, only concomitantly with C. albicans in 36 patients.
More than one kind of Candida species was isolated in 41
patients, with concomitant C. albicans and C. glabrata be-
ing the most common combination in approximately 90%
of these patients. In contrast, among 65 strains of Candida
isolated in patients in the 2006–2007 study, 56 strains of
C. albicans (86.2%), 8 strains of C. glabrata (12.3%), and 1
strain of C. tropicalis (1.5%) were identified, and no strains
of C. parapsilosis and C. krusei were detected. Thus, in the
2012–2013 study, the number of isolated strains of C.
glabrata was almost double that of the 2006–2007 study,
and the ratio of C. albicans to all Candida strains was
therefore significantly lower in the 2012–2013 study when
analyzed on a strain-basis or on a patient-basis. Thus, in
both patient-basis and strain-basis analyses, a statistical
difference was observed between the 2006–2007 study
and the 2012–2013 study (p < 0.01).Susceptibility to antifungal drugs
Since few (1 to 3 strains) of the Candida species other
than C. albicans and C. glabrata were isolated in either
study, MIC values of antifungal drugs against C. tropicalis,
C. parapsilosis, and C. krusei, which were never isolated
alone but only in combination with C. albicans and C.
glabrata, were not reliable. Therefore, the results of sus-
ceptibility testing mainly refer to the MICs of C. albicans
and C. glabrata (Table 3).Amphotericin B (AMPH-B)
The MIC was found to be low (≤2 μg/mL) in 63 (96.9%)
of the 65 strains in the 2006–2007 study and in 153
(99.4%) of the 154 strains in the 2012–2013 study. Two
strains of C. albicans in the 2006–2007 study and 1
strain of C. glabrata in the 2012–2013 study demon-
strated high MIC of over 16 μg/mL. However, the pres-
ence of resistant strains could not be detected in the
concentration range used in this analysis. There was no
obvious difference in the susceptibility of the 2 main
Candida species, C. albicans and C. glabrata, between
the 2 studies, with MIC90 values of 0.5 μg/mL and
2.0 μg/mL, respectively, in the 2006–2007 study and of
1.0 μg/mL and 1.0 μg/mL, respectively, in the 2012–
2013 study.
Table 1 Background variables of patients with oral candidiasis enrolled in the 2006–2007 and 2012–2013 studies
2006-2007 2012-2013
Test
Subjects number Total 57 112
Gender Male 19 (33.3) 30 (26.8) Fisher’s exact probability test
Female 38 (66.7) 82 (73.2) [2 × 2] N.S.
Age Average [max-min] 67.9 [26–90] 69.6 [21–97] Student’s t-test N.S.
Chief Complaints Heat sensation(HS) 23 (40.4) 46 (41.1)
Taste abnormality (TA) 2 (3.5) 0 (0)
Xerostomia (X) 5 (8.8) 26 (23.2)
Tylosis linguae (TL) 4 (7.0) 0 (0) Fisher’s exact probability test
Rubor/Erosion (R/E) 4 (7.0) 8 (7.1) [2 × 8]
HS + TA + X 9 (15.8) 16 (14.3) p < 0.05
HS + TA + R/E 5 (8.8) 8 (7.1)
HS + TL 5 (8.8) 8 (7.1)
Total 57 (100) 112 (100)
Systemic disease Yes 44 (77.2) 97 (86.6) Fisher’s exact probability test
None 13 (28.8) 15 (13.4) [2 × 2]
Total 57 (100) 112 (100) N.S.
Endocrine 22 (29.3) 22 (17.3)
Cardiovascular 18 (24.0) 28 (22.0)
Gastrointestinal 123 (16.0) 12 (9.4) Fisher’s exact probability test
Malignant tumor 8 (10.7) 12 (9.4) [2 × 7]
CNS 4 (5.3) 10 (7.9) N.S.
Viral 6 (8.0) 8 (6.3)
Autoimmune 5 (6.7) 35 (27.6)
Total 75 (100) 127 (100)
Steroid Dose 12 (21.1) 28 (25.0) Fisher’s exact probability test
Non-dosed 45 (78.9) 84 (75.0) [2 × 2]
Total 57 (100) 112 (100) N.S.
Denture Wearer 37 (64.9) 57 (50.9) Fisher’s exact probability test
Non-wearer 20 (35.1) 55 (49.1) [2 × 2]
Total 75 (100) 112 (100) N.S.
Oral candidiasis Pseudomembranous 42 (73.7) 42 (37.5)
Erythematous 11 (19.3) 52 (46.4) Fisher’s exact probability test
Hypertrophic 2 (3.5) 4 (3.6) [2 × 2]
Mixed 2 (3.5) 14 (12.5) N.S.
Total 55 (100) 112 (100)
Figure in parentheses represents the percentage except the age.
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Two strains of C. albicans in the 2006–2007 study and 2
strains of C. albicans and 1 strain of C. glabrata in the
2012–2013 study demonstrated high MIC of more than
32 μg/mL. There was no obvious difference in the sus-
ceptibility of C. albicans and C. glabrata between stud-
ies, with the 2006–2007 study demonstrating MIC90 of
0.5 μg/mL and 16 μg/mL, respectively, and the 2012–
2013 study, of 1.0 μg/mL and 8.0 μg/mL, respectively.Fluconazole (FLCZ)
MIC values were found below 64 μg/mL in 60 (92.3%)
of the 65 strains in the 2006–2007 study and in 146
(92.4%) of the 158 strains in the 2012–2013 study. High
MIC ≥64 μg/mL was recorded in 5 strains (9.5%) in the
2006–2007 study, of which 3 strains were C. albicans, 1
strain was C. glabrata, and 1 strain was C. tropicalis,
and in 12 strains (7.6%) in the 2012–2013 study, of
which 3 strains were C. albicans and 9 strains were
Table 2 Distribution of Candida species isolated from patients with oral candidiasis in the 2006–2007 and 2012–2013
studies
Candida species




Candida albicans (CA) 49 (86.0) 71 (63.4)
Candida glabrata (CG) 1 (1.8) 0 (0)
Candida tropicalis (CT) 0 (0) 0 (0)
Candida parapsilosis (CP) 0 (0) 0 (0)
Candida krusei (CK) 0 (0) 0 (0) Fisher’s exact probability test
Plural species isolated [2 × 10]
CA + CG 6 (10.5) 36 (32.1) p < 0.01
CA + CT 0 (0) 3 (2.7)
CA + CP 0 (0) 1 (0.9)
CA + CG + CT 1 (1.8) 0 (0)
CA + CP + CK 0 (0) 1 (0.9)
Total 57 (100) 112 (100)
Candida species
Total number of Candida strains isolated (%)
Test
2006-2007 2012-2013
Candida albicans 56 (86.2) 112 (72.8)
Candida glabrata 8 (12.3) 36 (23.4)
Candida tropicalis 1 (1.5) 3 (1.9) Fisher’s exact probability test
Candida parapsilosis 0 (0) 2 (1.3) [2 × 5]
Candida krusei 0 (0) 1 (0.6) p < 0.01
Total 65 (100) 154 (100
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resistant strains. A higher proportion of resistant C.
glabrata strains were found in the 2012–2013 study
(9/36, 25.0%) than in the 2006–2007 study (1/8, 12.5%).
An increase in MIC50 of C. glabrata from 2 μg/mL
in 2006–2007 to 16 μg/mL in 2012–2013 was also
observed.
Miconazole (MCZ)
The MIC of 60 (92.3%) of the 65 strains in the 2006–
2007 study and in 139 (88.0%) of the 158 strains in the
2012–2013 study were below 4 μg/mL. High MIC
(≥4 μg/mL) was recorded for 3 strains of C. albicans
(4.6%) and 2 strains of C. glabrata (25.0%) in 2006–
2007, and for 19 strains (12.0%) in 2012–2013, of which
6 strains were C. albicans (5.4%), 11 strains were C.
glabrata (30.6%), 1 strain was C. tropicalis (33.3%), and
1 strain was C. krusei (100%). Although MIC90 against
C. glabrata in the 2012–2013 study (16 μg/mL) was
higher than that in the 2006–2007 study (4.0 μg/mL), no
other significant differences were seen between studies.
The incidence of resistant C. glabrata was similar be-
tween the 2 studies at 25.0% (2/8 strains) and 30.6%
(11/36 strains), respectively.Itraconazole (ITCZ)
The MIC of 54 (83.1%) of the 65 strains in the 2006–
2007 study and of 127 (80.4%) of the 158 strains in the
2012–2013 study were less than 1 μg/mL. High MIC
(≥1 μg/mL) was recorded in 11 strains (16.9%) in 2006–
2007, of which 6 strains were C. albicans (10.7%), 4
strains were C. glabrata (50.0%), and 1 strain was C. tro-
picalis (100%), and in 31 strains (19.6%) in 2012–2013,
of which 5 strains were C. albicans (4.5%), 24 strains
were C. glabrata (66.7%), and 2 strains were C. tropicalis
(66.7%). There was a higher proportion of resistant
strains of C. glabrata against ITCZ in the 2012–2013
study (24/36 strains, 66.7%) than in the 2006–2007 study
(4/8 strains, 50.0%), but the difference was not statisti-
cally different. The MIC90 against C. glabrata was simi-
lar in both studies at >8.0 μg/mL, but that against C.
albicans in the 2012–2013 study (0.25 μg/mL) was lower
than that in the 2006–2007 study (1.0 μg/mL).
Micafungin (MCFG)
The MIC of 63 (96.9%) of the 65 strains in the 2006–
2007 study and of 157 (99.4%) of the 158 strains in the
2012–2013 study were >4 μg/mL. High MIC (≥4 μg/mL)
was recorded in only 2 strains (4.6%) in the 2006–2007
Table 3 Antifungal susceptibility profile, against amphotericin B, flucytosine, fluconazole, miconazole, itraconazole,
and micafungin, of Candida species isolated from patients with oral candidiasis in the 2006–2007 and 2012–2013
studies






<0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16
2006-2007 C. albicans 56 8 43 3 2 0.5 0.5
C. glabrata 8 1 2 2 2 1 0.5 2
C. tropicalis 1 1 0.25 0.25
2012-2013 C. albicans 112 4 12 86 9 1 0.5 1
C. glabrata 36 1 2 16 14 2 1 0.5 1
C. tropicalis 3 1 2 1 1
C. parapsilosis 2 2 <0.03 <0.03







<0.125 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
2006-2007 C. albicans 56 18 8 24 3 1 2 0.25 0.5
C. glabrata 8 4 1 1 2 <0.125 16
C. tropicalis 1 1 0.125 0.125
2012-2013 C. albicans 112 56 1 43 3 3 4 1 1 0.25 1
C. glabrata 36 20 6 6 2 1 1 <0.125 8
C. tropicalis 3 3 <0.125 <0.125
C. parapsilosis 2 2 2







<0.125 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
2006-2007 C. albicans 56 22 22 5 1 1 1 1 3 0.5 4
C. glabrata 8 1 2 2 1 1 1 2 >64
C. tropicalis 1 1 >64 >64
2012-2013 C. albicans 112 4 33 51 2 1 3 3 3 0.5 2
C. glabrata 36 4 1 5 6 7 7 2 16 64
C. tropicalis 3 1 2 32 32
C. parapsilosis 2 2 2 2







<0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16
2006-2007 C. albicans 56 2 22 20 8 1 3 0.125 0.25
C. glabrata 8 1 2 2 1 2 1 4
C. tropicalis 1 0.125 0.125
2012-2013 C. albicans 112 2 20 64 18 1 1 1 2 3 0.25 0.5
C. glabrata 36 1 5 12 7 3 3 2 3 2 16
C. tropicalis 3 1 1 1 1 4
C. parapsilosis 2 1 1 1-2 2
C. kurusei 1 1 4 4
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Table 3 Antifungal susceptibility profile, against amphotericin B, flucytosine, fluconazole, miconazole, itraconazole,








<0.015 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 >8
2006-2007 C. albicans 56 4 20 14 9 2 1 3 1 2 0.06 1
C. glabrata 8 1 1 1 1 1 1 2 0.05 >8
C. tropicalis 1 >8 >8
2012-2013 C. albicans 112 2 12 34 50 5 4 1 1 3 0.125 0.25
C. glabrata 36 1 3 3 5 9 8 2 5 1 >8
C. tropicalis 3 1 1 1 1 2
C. parapsilosis 2 1 1 0.25 0.25







<0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16
2006-2007 C. albicans 56 32 9 13 1 1 <0.03 0.06
C. glabrata 8 1 2 2 1 1 1 0.125 >16
C. tropicalis 1 1 0.06 0.06
2012-2013 C. albicans 112 95 12 2 1 1 1 <0.03 0.06
C. glabrata 36 16 1 1 3 5 6 1 2 1 0.125 1
C. tropicalis 3 2 1 <0.03 00.6
C. parapsilosis 2 2 <0.03 <0.03
C. kurusei 1 0.5 0.5
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rata, and 1 strain of C. glabrata in the 2012–2013 study.
Although the MIC90 against C. glabrata in 2012–2013
(1.0 μg/mL) was lower than in 2006–2007 (>16 μg/mL),
there was no other obvious differences in the susceptibility
of C. albicans and C. glabrata between studies.
Discussion
Non-C. albicans Candida (NCAC) strains have been iso-
lated in increasing numbers in medically compromised
patients including those with OC and denture stomatitis.
C. albicans remains the most common fungus associated
with infection, followed by C. glabrata. In clinically iso-
lated samples from the blood, urine, and tracheal secre-
tion of candidemia patients, the isolation frequency of C.
glabrata has been found to be 16–26%, which is the
highest among NCAC strains [17-20]. In the Prospective
Antifungal Therapy Alliance (PATH Alliance®), in which
3,648 patients with candidemia were enrolled from 2004
to 2008 in the US, the most common Candida species
was C. albicans (42.1%), followed by C. glabrata (26.7%),
and the proportion of candidemia caused by NCAC
strains was higher than that caused by C. albicans [21].
Such a high emergence of NCAC strains, especially of C.glabrata, in candidemia has recently been reported, with
a higher incidence of C. glabrata found from 2006 to
2010 (range: 4.8–23.5%, P = 0.024) in Brazil [22]. In
addition, the prevalence of infection due to a specific
Candida species may vary by geographic region [23].
However, few reports exist on differences in variation
of isolation frequency and its relation to candidemia in
oral candidiasis. In contrast, there are several reports on
oropharyngeal Candida infections due to C. glabrata
[24,25]. In the present study, the isolation frequency of
C. glabrata increased from 14.1% in 2006–2007 to 32.1%
in 2012–2013 when assessed by the number of patients,
indicating a similar tendency observed in Japanese OC
patients. The tendency of a shift of NCAC species would
also be attributable to frequent and wide use of azole
antifungal drugs, such as fluconazole, in the treatment
of mycosis [26]. Moreover, the isolation frequency of
NCAC strains, especially C. glabrata, was reported to in-
crease [26-28]. In Japan, as a result of a wide use of azole
antifungal drugs as the standard remedy for deep-seated
mycosis, it is supposed that the isolation frequency of
C. glabrata became high.
By comparing background data of OC patients in the
2012–2013 study and in the 2006–2007 study, the
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xerostomia as a chief complaint increased from 24.6% to
37.5% of patients, (2) autoimmune disorders as a sys-
temic disease increased from 6.7% to 27.6%, and (3) ery-
thematous OC as a type of OC increased from 19.3% to
46.4%. Differences in the frequency of xerostomia and
autoimmune disorders were associated with an increase
in patients with Sjögren’s syndrome, a chronic and pro-
gressive autoimmune disorder mainly characterized by
xerostomia. Differences in erythematous OC may be
partly attributed to an increase in simultaneous identifi-
cation of C. albicans and C. glabrata as observed in
32.1% of patients in the 2012–2013 study. In fact, cases
of mixed infection suggest that C. albicans enhances the
invasiveness of C. glabrata, and leads to increased lac-
tate dehydrogenase (LDH) release from a reconstituted
human oral epithelium (RHOE) in vitro [29]. Further-
more, LDH release paralleled the observed histological
damages in RHOE, which may be associated to the in-
crease in erythematous OC.
By comparing the susceptibilities of patients in the
2012–2013 study with that of the 2006–2007 study, azole
antifungal drugs (FLCZ, MCZ, and ITCZ) demonstrated
high MIC90 values against C. glabrata in both studies. In
particular, the MIC90 value of MCZ against C. glabrata in-
creased from 4 μg/mL (2006–2007) to 16 μg/mL (2012–
2013). Such high MIC values of azole antifungal drugs,
which suggest a decrease in the susceptibility of C. glab-
rata to these drugs, have been recognized in several stud-
ies [17-19,30]. Decreased susceptibility to FLCZ was
mainly seen against C. glabrata isolated from patients with
blood stream infections, with a dose-dependent suscepti-
bility rate of 76.5%, while the susceptibility rates of FLCZ
were 100% for C. albicans and C. parapsilosis [19]. Similar
results were also found for systemic candidiasis [18,20,23].
Decreases in the susceptibility of NCAC, especially of C.
glabrata, resulted from resistance to FLCZ, leading to oro-
pharyngeal Candida infections, which are more severe
and more difficult to treat in HIV-infected and cancer pa-
tients [30]. The development of resistance in C. glabrata
was observed against other azoles, such as ITCZ and keto-
conazole [20,31]. In addition, in the present study, al-
though statistical significance was not obtained, resistant
strains of C. glabrata increased from 50.0% (4/8) in the
2006–2007 study to 66.7% (24/36) in the 2012–2013
study. In cases of other azole antifungal drugs, FLCZ and
MCZ, resistant strains of C. glabrata increased slightly
from 12.5% to 25.0% and from 25.0% to 30.6%, respect-
ively. Thus, a tendency for increased isolation frequencies
of resistant C. glabrata against azole antifungal drugs, es-
pecially ITCZ have been observed. Frequent exposure of
antifungal drugs, especially azoles, is known to lead to an
increase in resistant Candida strains, which has been re-
ported since fluconazole was clinically available in 1989.After that new azole antifungal drugs, such as itraconazole
and voliconazole, have been widely used for deep-seated
mycosis. Thus, increases in clinically available antifungal
azole drugs and in their clinical usages for the treatment
of deep-seated mycosis could lead to an increment of re-
sistant Candida strains. This tendency would be still con-
tinuing during the period of 2006–2013.
Conclusions
In oral Candida species isolated from OC patients, the ra-
tio of C. glabrata to C. albicans increased in the 2012–
2013 study as compared to the 2006–2007 study, accom-
panying the tendency of increases in tolerant strains of C.
glabrata against azole antifungal drugs and in cases of
autoimmune disease. The higher isolation frequency of C.
glabrata, especially of co-isolation frequency with C. albi-
cans, may be associated with the increase in erythematous
OC. Considering the increase in C. glabrata resistant
strains against azoles, selection of appropriate antifungal
drugs and dosing regimens against resistant C. glabrata,
as well as against C. albicans is important.
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